Abstract 1956P
Background
Alternative promoters and splice sites enable most human genes to generate multiple transcript isoforms, significantly increasing phenotypic complexity. Large-scale tumor RNA-seq analysis has demonstrated widespread splicing aberrations and alternative promoter activation in cancer, implicating isoform dysregulation as a crucial factor in carcinogenesis.
Methods
By integrating RNA-seq data from TCGA, PCAWG, and GTEx projects, we reconstructed individual transcript sequences expressed in more than 26000 cancer and normal samples, elucidating a comprehensive panorama of alternative isoform utilization across 39 tissues and 38 cancer types.
Results
Our isoform-centric analysis reveals that (1) global transcriptome architecture is distinct across tissues, between cancer and normal samples of the same tissue origin, and between cancer molecular subtypes—even at sub-gene resolution; (2) alternative promoter usage and splicing together contribute to ∼40% of transcriptome heterogeneity across tissues and 50-60% within tissues and cancer types; (3) cancer frequently increases the usage of aberrant tumor suppressor gene isoforms lacking protein-coding potential; (4) differentially used isoforms hold significant prognostic value in various cancers, with aberrant transcripts from NRG1, CAMTA1, and LRP1B demonstrating the strongest association with survival; and (5) co-occurring differential splicing events within single RNA molecules may offset each other's frame-shifting effects.
Conclusions
Our findings indicate cancer frequently dysregulates alternative isoform usage, perturbing key oncogenic pathways. This highlights the value of isoform-resolution transcriptome profiling for improved individualized cancer diagnostics and treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korea Advanced Institute of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
44P - Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial
Presenter: Mariano Ponz-Sarvise
Session: Poster session 13
47P - First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
Presenter: Shukui Qin
Session: Poster session 13
48P - Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study
Presenter: Maria Pia Quitadamo
Session: Poster session 13
49P - Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?
Presenter: Lidia Rita Corsini
Session: Poster session 13
50P - Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
Presenter: yunxin lu
Session: Poster session 13
52P - Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial
Presenter: Ji Ma
Session: Poster session 13